2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

 

Call-center:
(+373-22) 400500

Anti-corruption line:
(+373-22) 400500

Visit of ELSEVIER Company Representatives to AGEPI

10/22/2013

On 17 October this year, the ELSEVIER company representatives undertook an information visit to the State Agency on Intellectual Property (AGEPI). The delegation was composed of the Regional Country Manager, South-Eastern Europe Catalin Teoharie and Customer Development Manager Agata Jablonka.

The aim of the visit was to familiarize the Moldovan institutions and organizations involved in the research & innovation and intellectual property protection process with the products and programs of the ELSEVIER Company and establish cooperation relations in order to give users of scientific information access to these products.

During the meeting with the AGEPI specialists, Catalin Teoharie presented ELSEVIER as being one of the world’s leading providers of scientific and medical literature in the field, which serves more than 30 million scientists, students and health professionals worldwide.

As company partners are counted over 7,000 magazine editors, 70,000 members of the editorial board, 300,000 reviewers and 600,000 authors, who have one goal: to help specialists in the field of science and health by providing world class information and innovative tools, information that support productivity growth and improvement of outcomes in this area. As founding editor of global programs, ELSEVIER provides free or low-cost access to science and public health in developing countries.

Thus, in order to disseminate information about the activities and products of the company, ELSEVIER representatives had several meetings with the research institutions, such as the Academy of Sciences of Moldova, State University, etc.

ELSEVIER is part of Reed Elsevier Group which has its headquarters in Amsterdam. The ELSEVIER Company was founded in 1880 and is specialized in the publication of medical and scientific literature.

More detailed information about the ELSEVIER Company at: http://www.elsevier.com/